Evidence map›Paper›PMID 27893488›Full record

ArticleEpidemiology (Cambridge, Mass.)2017

Pregnancy and HIV Disease Progression in an Early Infection Cohort from Five African Countries.

Kristin M Wall, Wasima Rida, Lisa B Haddad, Anatoli Kamali, Etienne Karita, Shabir Lakhi, William Kilembe, Susan Allen, Mubiana Inambao, Annie H Yang and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Epidemiology (Cambridge, Mass.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Kristin M WallFrom the aDepartment of Epidemiology, Rollins School of Public Health, Laney Graduate School, Emory University, Atlanta, GA; bRwanda Zambia HIV Research Group, Department of Pathology & Laboratory Medicine, School of Medicine and Hubert Department of Global Health and the Department of Epidemiology, Rollins School of Public Health, Laney Graduate School, Emory University, Atlanta, GA; cBiostatistics Consultant, Arlington, VA; dDepartment of Gynecology and Obstetrics, Emory University, School of Medicine, Atlanta, GA; eMedical Research Council/Uganda Virus Research Unit, Research Unit on AIDS, Entebbe, Uganda; fRwanda Zambia HIV Research Group, Department of Pathology & Laboratory Medicine, School of Medicine and Hubert Department of Global Health and the Department of Epidemiology, Rollins School of Public Health, Laney Graduate School, Emory University, Kigali, Rwanda; gRwanda Zambia HIV Research Group, Department of Pathology & Laboratory Medicine, School of Medicine and Hubert Department of Global Health and the Department of Epidemiology, Rollins School of Public Health, Laney Graduate School, Emory University, Lusaka, Zambia; hRwanda Zambia HIV Research Group, Department of Pathology & Laboratory Medicine, School of Medicine and Hubert Department of Global Health and the Department of Epidemiology, Rollins School of Public Health, Laney Graduate School, Emory University, Ndola, Zambia; iDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; jThe Aurum Institute, Johannesburg and Rustenburg, South Africa; kKenya AIDS Vaccine Initiative Institute of Clinical Research, University of Nairobi, Nairobi, Kenya; lCentre for Geographic Medicine-Coast/Kenya Medical Research Institute, Kilifi, Kenya; mUniversity of Oxford, Oxford, United Kingdom; nDesmond Tutu HIV Centre, University of Cape Town, Cape Town, Republic of South Africa; oSchool of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; pInternational AIDS Vaccine Initiative, New York, NY; and qDepartment of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA.
Wasima Rida
Lisa B Haddad
Anatoli Kamali
Etienne Karita
Shabir Lakhi
William Kilembe
Susan Allen
Mubiana Inambao
Annie H Yang
Mary H Latka
Omu Anzala
Eduard J Sanders
Linda-Gail Bekker
Vinodh A Edward
Matt A Price
Emory University · US

Funding

Soweto Clinical Trials UnitUM1AI069453 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI Glenda E Gray, Lerato Mohapi · 2012 to 2026
$40.9M
NIAID NIH HHS UM1 AI069453
6 · The paper itself

Abstract

backgroundUnderstanding associations between pregnancy and HIV disease progression is critical to provide appropriate counseling and care to HIV-positive women.

methodsFrom 2006 to 2011, women less than age 40 with incident HIV infection were enrolled in an early HIV infection cohort in Kenya, Rwanda, South Africa, Uganda, and Zambia. Time-dependent Cox models evaluated associations between pregnancy and HIV disease progression. Clinical progression was defined as a single CD4 measurement <200 cells/μl, percent CD4 <14%, or category C event, with censoring at antiretroviral (ART) initiation for reasons other than prevention of mother-to-child transmission (PMTCT). Immunologic progression was defined as two consecutive CD4s ≤350 cells/μl or a single CD4 ≤350 cells/μl followed by non-PMTCT ART initiation. Generalized estimating equations assessed changes in CD4 before and after pregnancy.

resultsAmong 222 women, 63 experienced clinical progression during 783.5 person-years at risk (8.0/100). Among 205 women, 87 experienced immunologic progression during 680.1 person-years at risk (12.8/100). The association between pregnancy and clinical progression was adjusted hazard ratio [aHR] = 0.7; 95% confidence interval (CI): 0.2, 1.8. The association between pregnancy and immunologic progression was aHR = 1.7; 95% CI: 0.9, 3.3. Models controlled for age; human leukocyte antigen alleles A*03:01, B*45, B*57; CD4 set point; and HIV-1 subtype. CD4 measurements before versus after pregnancies were not different.

conclusionsIn this cohort, pregnancy was not associated with increased clinical or immunologic HIV progression. Similarly, we did not observe meaningful deleterious associations of pregnancy with CD4s. Our findings suggest that HIV-positive women may become pregnant without harmful health effects occurring during the pregnancy. Evaluation of longer-term impact of pregnancy on progression is warranted.

Indexed as

AdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesDisease ProgressionFemaleHIV InfectionsHumansInfectious Disease Transmission, VerticalKenyaPregnancyPregnancy Complications, InfectiousProportional Hazards ModelsRwandaSouth AfricaAnti-HIV Agents

Identifiers

PMID27893488
PMCPMC5287431
OpenAlexW2556688003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.